share_log

Independent Director Scott Schlackman Sold A Bunch Of Shares In Medifast

Independent Director Scott Schlackman Sold A Bunch Of Shares In Medifast

獨立董事斯科特·施拉克曼出售了Medifast的大量股票
Simply Wall St ·  03/15 06:14

Anyone interested in Medifast, Inc. (NYSE:MED) should probably be aware that the Independent Director, Scott Schlackman, recently divested US$109k worth of shares in the company, at an average price of US$39.46 each. The eyebrow raising move amounted to a reduction of 37% in their holding.

任何對Medifast, Inc.(紐約證券交易所代碼:MED)感興趣的人都應該知道,獨立董事斯科特·施拉克曼最近剝離了該公司價值10.9萬美元的股份,平均每股價格爲39.46美元。令人驚訝的舉動使他們的持股量減少了37%。

Medifast Insider Transactions Over The Last Year

去年的Medifast內幕交易

In the last twelve months, the biggest single sale by an insider was when the insider, Constance Hallquist, sold US$415k worth of shares at a price of US$73.87 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of US$34.57. So it may not shed much light on insider confidence at current levels.

在過去的十二個月中,知情人最大的一次出售是知情人康斯坦斯·哈爾奎斯特以每股73.87美元的價格出售了價值41.5萬美元的股票。雖然我們通常不喜歡看到內幕銷售,但更令人擔憂的是是否以較低的價格進行銷售。好消息是,此次大宗銷售遠高於當前的34.57美元。因此,在當前水平上,這可能無法爲內部信心提供太多啓示。

In the last twelve months insiders purchased 675.43 shares for US$55k. On the other hand they divested 8.37k shares, for US$523k. In total, Medifast insiders sold more than they bought over the last year. The average sell price was around US$62.55. It is certainly not great to see that insiders have sold shares in the company. But the selling was at much higher prices than the current share price (US$34.57), so it probably doesn't tell us a lot about the value on offer today. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

在過去的十二個月中,內部人士以5.5萬美元的價格購買了675.43股股票。另一方面,他們以52.3萬美元的價格剝離了8.37萬股股票。去年,Medifast內部人士的總銷售量超過了他們的購買量。平均售價約爲62.55美元。看到內部人士出售該公司的股票肯定不是一件好事。但是此次出售的價格遠高於當前的股價(34.57美元),因此它可能無法告訴我們很多有關當今股票價值的信息。你可以在下面看到過去 12 個月的內幕交易(公司和個人)的直觀描述。通過點擊下面的圖表,你可以看到每筆內幕交易的確切細節!

insider-trading-volume
NYSE:MED Insider Trading Volume March 15th 2024
紐約證券交易所:MED 內幕交易量 2024 年 3 月 15 日

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你喜歡買內部人士買入而不是賣出的股票,那麼你可能會喜歡這份免費的公司名單。(提示:業內人士一直在購買它們)。

Does Medifast Boast High Insider Ownership?

Medifast 是否擁有很高的內部所有權?

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From our data, it seems that Medifast insiders own 1.8% of the company, worth about US$7.0m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

許多投資者喜歡查看公司內部人士擁有多少股份。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。從我們的數據來看,Medifast內部人士似乎擁有該公司1.8%的股份,價值約700萬美元。總的來說,這種所有權水平並不那麼令人印象深刻,但肯定總比沒有好!

What Might The Insider Transactions At Medifast Tell Us?

Medifast的內幕交易能告訴我們什麼?

An insider sold Medifast shares recently, but they didn't buy any. And our longer term analysis of insider transactions didn't bring confidence, either. When you consider that most companies have higher levels of insider ownership, we're a little wary. So we'd only buy after very careful consideration. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. When we did our research, we found 2 warning signs for Medifast (1 shouldn't be ignored!) that we believe deserve your full attention.

一位內部人士最近出售了Medifast的股票,但他們沒有購買任何股票。而且,我們對內幕交易的長期分析也沒有帶來信心。當你考慮到大多數公司的內部所有權水平更高時,我們有點警惕。因此,我們只有在經過仔細考慮後才會購買。因此,雖然了解內部人士在買入或賣出方面的所作所爲很有幫助,但了解特定公司面臨的風險也很有幫助。當我們進行研究時,我們發現了 Medifast 的 2 個警告信號(1 個不容忽視!)我們認爲值得你全神貫注。

Of course Medifast may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

當然,Medifast可能不是最值得購買的股票。因此,您可能希望看到這個免費的高質量公司集合。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論